TOP TEN perturbations for NM_000152 (Homo sapiens)

Organism: Homo sapiens
Gene: NM_000152
Selected probe(set): 202812_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of NM_000152 (202812_at) across 5339 perturbations tested by GENEVESTIGATOR:

F. tularensis study 1 (tularensis Schu S4) / uninfected peripheral blood monocyte sample

Relative Expression (log2-ratio):-2.870614
Number of Samples:4 / 6
Experimental F. tularensis study 1 (tularensis Schu S4)
Peripheral blood monocytes infected with the Schu S4 isolate of Francisella tularensis (100 MOI) for 24 hours.
Control uninfected peripheral blood monocyte sample
Peripheral blood monocytes uninfected.

F. tularensis study 1 (novicida) / uninfected peripheral blood monocyte sample

Relative Expression (log2-ratio):-2.5968657
Number of Samples:4 / 6
Experimental F. tularensis study 1 (novicida)
Peripheral blood monocytes infected with the Francisella tularensis subspecies novicida isolate U112 (100 MOI) for 24 hours.
Control uninfected peripheral blood monocyte sample
Peripheral blood monocytes uninfected.

SDF study 4 / untreated MDA Mb231 cell sample

Relative Expression (log2-ratio):2.4142542
Number of Samples:3 / 6
Experimental SDF study 4
MDA Mb231 cells treated with 75nM stromal derived factor (SDF; Cxcl12) for 6h.
Control untreated MDA Mb231 cell sample
Untreated MDA Mb231 cells harvested after 6h.

monocyte activation study 1 (NOD2L/TLR/1L; 24h) / monocyte activation study 1 (NOD2L/TLR/1L; 6h)

Relative Expression (log2-ratio):2.3223972
Number of Samples:5 / 5
Experimental monocyte activation study 1 (NOD2L/TLR/1L; 24h)
Monocytes were isolated from five healthy donors, cultured in RPMI with 10% vitamin D?sufficient (100 nM) human serum and activated for 24 hours with 1 ug/ml muramyl dipeptide (nucleotide-binding oligomerization domain-containing protein 2 ligand, NOD2L) and 1 ug/ml mycobacterial 19-kDa triacylated lipopeptide (TLR2/1 ligand, TLR2/1L). This type of activation is via nucleotide-binding oligomerization domain-containing protein 2 (NOD2) and heterodimeric Toll-like receptor 2 and Toll-like receptor 1 (TLR2/1).
Control monocyte activation study 1 (NOD2L/TLR/1L; 6h)
Monocytes were isolated from five healthy donors, cultured in RPMI with 10% vitamin D?sufficient (100 nM) human serum and activated for 6 hours with 1 ug/ml muramyl dipeptide (nucleotide-binding oligomerization domain-containing protein 2 ligand, NOD2L) and 1 ug/ml mycobacterial 19-kDa triacylated lipopeptide (TLR2/1 ligand, TLR2/1L). This type of activation is via nucleotide-binding oligomerization domain-containing protein 2 (NOD2) and heterodimeric Toll-like receptor 2 and Toll-like receptor 1 (TLR2/1).

monocyte activation study 1 (TLR/1L; 24h) / monocyte activation study 1 (TLR/1L; 6h)

Relative Expression (log2-ratio):2.0920935
Number of Samples:5 / 5
Experimental monocyte activation study 1 (TLR/1L; 24h)
Monocytes were isolated from five healthy donors, cultured in RPMI with 10% vitamin D?sufficient (100 nM) human serum and activated for 24 hours with 1 ug/ml mycobacterial 19-kDa triacylated lipopeptide (TLR2/1 ligand, TLR2/1L). This type of activation is via heterodimeric Toll-like receptor 2 and Toll-like receptor 1 (TLR2/1).
Control monocyte activation study 1 (TLR/1L; 6h)
Monocytes were isolated from five healthy donors, cultured in RPMI with 10% vitamin D?sufficient (100 nM) human serum and activated for 6 hours with 1 ug/ml mycobacterial 19-kDa triacylated lipopeptide (TLR2/1 ligand, TLR2/1L). This type of activation is via heterodimeric Toll-like receptor 2 and Toll-like receptor 1 (TLR2/1).

HIF-1a/HIF-2a depletion study 1 (hypoxia; HK2) / HIF-1a/HIF-2a depletion study 1 (normoxia; AB81)

Relative Expression (log2-ratio):-1.9545364
Number of Samples:3 / 3
Experimental HIF-1a/HIF-2a depletion study 1 (hypoxia; HK2)
Proximal tubule epithelial cell line HK-2 with shRNA-mediated stable knock-down of HIF-1a and HIF-2a (Hypoxia-inducible factor 1-alpha and Hypoxia-inducible factor 2-alpha) 24 hours after treatment with hypoxia (20% O2). HK-2 cells were cultured in DMEM/F-12 supplemented with 10% fetal calf serum (FCS), 1% ITS, hydrocortisone, and antibiotics. The cells were incubated at 37 ?C.
Control HIF-1a/HIF-2a depletion study 1 (normoxia; AB81)
Human podocyte cells AB81 with shRNA-mediated stable knock-down of HIF-1a and HIF-2a (Hypoxia-inducible factor 1-alpha and Hypoxia-inducible factor 2-alpha) 24 hours after treatment with normoxia (20% O2). Conditionally immortalized human podocytes AB81 were cultured under permissive conditions (33 ?C) in RPMI-1640 supplemented with 10% FBS, antibiotics, and 1% ITS. Differentiation was induced by thermoshift to 37 ?C in 6-well plates.

atopic dermatitis study 12 (non-lesional; adults) / atopic dermatitis study 12 (non-lesional; children)

Relative Expression (log2-ratio):1.948061
Number of Samples:20 / 19
Experimental atopic dermatitis study 12 (non-lesional; adults)
Unaffected skin biopsy samples from adult patients (age range 18-73 years) with long-standing atopic dermatitis.
Control atopic dermatitis study 12 (non-lesional; children)
Unaffected buttock skin biopsy samples from pediatric patients (age range 3 months-5 years) with early-onset atopic dermatitis. All patients had moderate-to-severe disease (SCORAD score: mean, 57.8; range, 33-84) with recent-onset (within the previous 6 months). Systemic immunosuppressants within the past 4 weeks, topical steroids or immunomodulators within 1 week, or moisturizers within 12 hours before evaluation were restricted. Patients with active skin infections were excluded.

conditioned medium study 1 (HS5) / untreated monocyte (CD14+) sample

Relative Expression (log2-ratio):1.8940887
Number of Samples:2 / 2
Experimental conditioned medium study 1 (HS5)
CD14+ monocytes treated with HS5 conditioned medium (CM) for 48h.
Control untreated monocyte (CD14+) sample
Untreated CD14+ monocytes from two different donors.

kidney transplantation study 12 (4 week) / normal T-cell (CD4+) sample

Relative Expression (log2-ratio):1.8688631
Number of Samples:2 / 5
Experimental kidney transplantation study 12 (4 week)
CD4+ T-cell samples derived from kidney transplant patients 4 weeks post-transplantation. Samples were collected 4 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH).
Control normal T-cell (CD4+) sample
CD4+ T-cell samples derived from healthy control subjects.

oncolytic herpes simplex virus study 2 / mock infected peripheral nerve sheath tumor (S462) cell sample

Relative Expression (log2-ratio):-1.7783604
Number of Samples:3 / 3
Experimental oncolytic herpes simplex virus study 2
Human malignant peripheral nerve sheath tumor (S462) cells infected with G207, an ICP34.5-deleted oncolytic herpes simplex virus (oHSV) for 6 hours.
Control mock infected peripheral nerve sheath tumor (S462) cell sample
Human malignant peripheral nerve sheath tumor (S462) cells mock infected for 6 hours.